NAD+ Precursor Supplementation in Friedreich's Ataxia
Status:
Recruiting
Trial end date:
2023-04-10
Target enrollment:
Participant gender:
Summary
The primary objective is to test the safety and tolerability of short-term therapy with a
nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's
Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%.
A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle
bioenergetics.